Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9998)
◆英語タイトル:Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9998
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Venture Financing 13
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Licensing Agreements 16
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Equity Offering 17
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc – Key Competitors 28
Revance Therapeutics Inc – Key Employees 29
Revance Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2018: Revance releases third quarter 2018 results 31
Aug 02, 2018: Revance releases second quarter 2018 results 33
May 08, 2018: Revance Releases First Quarter 2018 Results 34
Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 36
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 37
May 09, 2017: Revance Releases First Quarter 2017 Results 38
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
Oct 11, 2018: Revance Therapeutics appoints Tobin C. Schilke as chief financial officer 41
May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 42
May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 43
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 44
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 45
Product News 46
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 46
Clinical Trials 47
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 47
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 49
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 51
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 52
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 53
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 54
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 55
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc, Key Competitors 28
Revance Therapeutics Inc, Key Employees 29
Revance Therapeutics Inc, Subsidiaries 30

List of Figures
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報(Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆